A 35-year-old woman who has been using a combined oral contraceptive pill (30 µg ethinyl estradiol + norethisterone) for 8 years attends her annual check-up. She is a non-smoker with no significant medical history, blood pressure 128/82 mmHg, and BMI 24 kg/m². She reports occasional headaches but denies visual disturbances, chest pain, or leg swelling. On direct questioning, she mentions that her headaches have become slightly more frequent over the past 2 months. What is the most appropriate next step?

Explanation

## Headache and Oral Contraceptive Pill Use: Risk Stratification ### The Clinical Dilemma Headaches are among the most common complaints in COC users, occurring in 10–20% of users. However, the **type and characteristics** of headache determine whether the COC should be continued or discontinued. **Key Point:** The critical distinction is between **migraine without aura** (safe to continue COC) and **migraine with aura** (absolute contraindication to estrogen-containing COCs due to increased stroke risk). ### Why Detailed Assessment Is Essential The WHO and most international guidelines recommend: 1. **Characterize the headache:** Onset, frequency, severity, associated symptoms (visual disturbances, photophobia, nausea, focal neurological signs) 2. **Distinguish migraine from tension headache:** Migraine is pulsatile, unilateral, and often disabling; tension headache is bilateral and pressure-like 3. **Screen for aura:** Aura is a reversible neurological symptom (visual scotoma, hemianopia, paresthesia, speech disturbance) that precedes the headache by 5–60 minutes 4. **Assess temporal relationship:** Did headaches start after COC initiation? Have they worsened since starting? ### Risk Stratification Table | Headache Type | COC Safety | Action | |---|---|---| | Tension headache (new or worsening) | Safe | Continue COC; consider analgesics, stress management | | Migraine without aura (new or worsening) | Safe | Continue COC; consider prophylaxis (propranolol, amitriptyline) | | Migraine with aura (any) | **CONTRAINDICATED** | Discontinue COC; switch to POP, IUD, or barrier method | | Migraine with focal neurological signs | **CONTRAINDICATED** | Discontinue immediately; urgent neurology referral | **High-Yield:** Migraine with aura + estrogen = increased stroke risk (relative risk ~4–6). This is an **absolute contraindication** to COCs. ### Clinical Pearl Many women experience mild headaches with COCs that are **not migrainous** and do not warrant discontinuation. A careful history focusing on aura symptoms is the key discriminator. ### Why Triptans Are Not the Solution While triptans are effective for acute migraine, they do not address the underlying increased stroke risk in women with migraine with aura who use estrogen. Triptans are also contraindicated in migraine with aura due to vasoconstrictive effects. **Mnemonic: AURA** — Assess headache type, Understand aura presence, Risk-stratify, Act (continue or discontinue).